Patient preference should be considered because medications don't work if adherence is poor, the experts noted.
Ongoing access to diabetes self-management education and support (DSMES) and promoting good medication adherence are among the keys to managing hyperglycemia, or high blood glucose, in patients with type 2 diabetes (T2D), according to a joint statement from the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA), released this week at the EASD annual meeting in Munich, Germany.
The statement was published in Diabetologia, the official journal of EASD, and in Diabetes Care, the official journal of ADA.
The experts who developed the consensus statement said that patient preference should be a major factor in driving treatment choices, because their preferences for the delivery method—such as a pill vs an injection—or things like side effects or cost could have an impact on adherence. And if patients don’t take medications, they don’t work, regardless of what evidence showed in a clinical trial.
The emphasis on giving patients more access to DSMES is key, because current reimbursement models, including those in Medicare, may limit the number of hours or points at which a patient can meet with a diabetes educator. A position statement from the American Association of Diabetes Educators, ADA, and the Academy of Nutrition and Dietetics called for education at discrete points in the life cycle of diabetes: (1) at diagnosis, (2) at annual assessments, (3) when new complications occur, and (4) during transitions in life and care.
While there are new digital diabetes management tools available, evidence shows that these work best when patients can combine them with contact with a trained professional (see our special issue of Evidence-Based Diabetes Management™).
Among other recommendations, the statement calls for:
Experts called for more research into combinations of glucose lowering therapies. “As cost implications for these various approaches is enormous, evidence is desperately needed,” the committee said in a statement. “Defining optimal cost-effective approaches to care, particularly in the management of patients—including those with multi-morbidity—is essential.”
The committee said the giant cardiovascular outcomes trials raise important questions: do benefits, including renal benefits, extend to low-risk patients? If so, for which population groups?
However, the cardiovascular outcomes trials that have demonstrated unexpected cardiovascular benefits in T2D medications may be up for re-examination. A decade after their inception, FDA has scheduled a 2-day review of these giant studies on October 24-25, 2018. While there are certainly more choices in T2D therapy than ever, the need to examine each one for potential heart attack and stroke risks has substantially increased their cost.
“The management of hyperglycemia in type 2 diabetes has become enormously complex with the number of glucose-lowering medications now available,” the EASD/ADA panel said. While diet and exercise remain the foundation of good care, metformin followed by other medications based on individual patient comorbidities is recommended, “as we await answers to the many questions that remain.”
Reference
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [published online October 5, 2018]. Diabetologia. 2018; doi.org/10.1007/s00125-018-4729-5.
Research Points to Potential MCIDs in Diabetes Distress Scale–17
November 29th 2023Researchers identified a value of at least 0.25 to be a minimal clinically important difference (MCID) in diabetes distress, and MCID values of 0.38 and 0.39 for emotional and interpersonal distress subscales and physician and regimen distress subscales, respectively.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Study Reveals Factors That Further Increase Colorectal Cancer Risk for Adults With T2D
November 14th 2023The strongest associations between diabetes and colorectal cancer risk were observed in participants with a recent diabetes diagnosis and those who had not undergone recent colonoscopy, underscoring the significance of cancer screening.
Read More